Compare · BIOA vs PFE
BIOA vs PFE
Side-by-side comparison of BioAge Labs Inc. (BIOA) and Pfizer Inc. (PFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOA and PFE operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PFE is the larger of the two at $153.59B, about 202.9x BIOA ($757.0M).
- Over the past year, BIOA is up 289.7% and PFE is up 17.1% - BIOA leads by 272.6 points.
- PFE has been more active in the news (10 items in the past 4 weeks vs 5 for BIOA).
- PFE has more recent analyst coverage (25 ratings vs 13 for BIOA).
- Company
- BioAge Labs Inc.
- Pfizer Inc.
- Price
- $17.03-1.25%
- $26.98+1.20%
- Market cap
- $757.0M
- $153.59B
- 1M return
- +3.94%
- -1.21%
- 1Y return
- +289.70%
- +17.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 5
- 10
- Recent ratings
- 13
- 25
Pfizer Inc.
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Prevnar 13/Prevenar 13 (pediatric/adult), Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Pfizer-BioNTech COVID-19 vaccine brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa/Staquis brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Syapse, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Latest BIOA
- Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)
- SEC Form DEFA14A filed by BioAge Labs Inc.
- SEC Form DEF 14A filed by BioAge Labs Inc.
- BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP
- BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference
- SEC Form 4 filed by Rubin Paul D
- SEC Form 144 filed by BioAge Labs Inc.
- Needham initiated coverage on BioAge Labs with a new price target
- SEC Form S-3ASR filed by BioAge Labs Inc.
- SEC Form S-8 filed by BioAge Labs Inc.
Latest PFE
- Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
- Pfizer Declares Second-Quarter 2026 Dividend
- Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
- U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- SEC Form 4 filed by Bourla Albert
- SEC Form 4 filed by Bourla Albert
- SEC Form 3 filed by new insider Hancock Dennis P
- Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
- Telix Strengthens Board with Additional Director Appointments
- AI-Enhanced Robotics in Pharma Manufacturing Signals Major Efficiency, Margin Expansion Opportunities